![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
ABSTRACT
Purpose
To determine the clinical benefits of Meibomian gland expression therapy for the treatment of dry-eye disease caused by Meibomian gland dysfunction (MGD).
Methods
In a prospective randomized controlled double-masked trial, 87 eyes of 44 patients with MGD and dry-eye symptoms were enrolled. Patients were randomly assigned into two groups; a study group that received therapeutic Meibomian gland expression once every month, and a control group that received sham treatment. All patients received treatment with artificial tears.
Results
One week after the first treatment, the Ocular Surface Disease Index (OSDI) score improved significantly in the study group (mean change −18.5 ± 21.2, p = .01) but not in the control group (−3.8 ± 15.8, p = .16); after 1 month, both groups improved significantly (−20.5 ± 19 p = .001 in the study group and −6.5 ± 11, p = .016 in the control group). The improvement continued at 2 months in the study group (−28.4 ± 26.1, P < .0001) and in the control group (−9.6 ± 9.9, p = .007). The blepharitis questionnaire score improved in the study group compared to controls after 1 week (−9.95 ± 12.52 versus −1.77 ± 9.1, p = .03) 1 month (−11.5 ± 10.9 versus −1.1 ± 9.4, p = .02) and 2 months (−16.5 ± 8.0 versus −8.8 ± 11.7, p = .02). Burning sensation was significantly reduced only in the study group. Mean change after 2-month treatment was −2.00 ± 1.2583 (p < .0001) vs −0.67 ± 1.44 (p = .08). The trend was similar in Eyelid scales. Conjunctival hyperemia improved only in the study group 1 week after the treatment (−0.12 ± 0.32 p = .03).
Conclusion
Therapeutic Meibomian gland expression improves dry-eye symptoms in subjects with MGD, compared to conventional treatment with artificial tears.
Conflicts of interest and source of funding
No funding or conflicts of interest to disclose.
Financial support
None